Has Sheldon Genack, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,970 in general payments to Sheldon Genack, MD across 92 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sheldon Genack, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sheldon Genack, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sheldon Genack, MD

Otolaryngology · Hewlett, NYNPI 1821104308

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.4% of the total across 92 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations.

$2,970in general payments, 2019–2025

Across 92 payments — averaging $32.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Regeneron Healthcare Solutions, Inc.$485
GSK$430
Sanofi$380
Optinose US, Inc.$298
Alk-abello, Inc$291
Neurent Medical Limited$218
plus $868 from 9 others

$68,254in research payments, 2019–2025

Across 6 payments — averaging $11,376 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AstraZeneca$68K

What the payments were for

Food & beverage$2,86296%
Education$1084%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Regeneron Healthcare Solutions, Inc.	16	$485
GSK	17	$430
Sanofi	13	$380
Optinose US, Inc.	14	$298
Alk-abello, Inc	13	$291
Neurent Medical Limited	2	$218
Phathom Pharmaceuticals, Inc.	2	$178
Boston Scientific	1	$162
Inspire Medical Systems, Inc.	3	$150
Intersect ENT, Inc.	3	$132
Sanofi-aventis U.S. LLC	2	$108
AbbVie	2	$53
Hikma Pharmaceuticals USA	2	$41
Amgen	1	$27
Galderma Laboratories, L.p.	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,970 in reported general payments places this provider in the 70th percentile of 701 otolaryngology providers in New York.

See all otolaryngology providers in New York →

Medicare billing

Part B allowed, 2024

$383,799

Medicare patients

1,250

Services billed

4,806

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dupixent SyringeDupilumab	29	$117,846
Ipratropium Bromide	102	$2,400
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth	14	$1,870
Fluocinolone Acetonide Oil	29	$1,129
Ofloxacin	23	$1,127
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort	17	$903
Omeprazole	130	$714
Fluticasone Propionate	51	$638
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav	34	$455
Methylprednisolone	61	$435
Famotidine	43	$256
Azelastine Hcl	12	$201
Prednisone	14	$43
Pantoprazole Sodium	11	$31

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Hewlett

Robert KellmanSyracuse$2.5M
Roheen RaithathaNew York$830K
Nora PerkinsAlbany$300K
Moshe EphratNew Hyde Park$250K
Gavin SetzenAlbany$243K
Habibullah JamalRye Brook$179K
Albert JenFlushing$171K
Dennis KrausNew York$159K
Nitin BhatiaWhite Plains$120K
Sveta KarelskyRochester$101K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →